Gestrinone vs leuprolin
Dysmenorrhoea, verbal rating scale · women with symptomatic endometriosis
1 finding from 1 review
- no estimate extracted1 study · 55 participantsLow
Findings
What do systematic reviews say?
151 questions · 153 findings · 18 reviews
No studies found 19 · 12.4%GRADE not reported 18 · 11.8%Very low 26 · 17%Low 57 · 37.3%Moderate 27 · 17.6%High 6 · 3.9%
Gestrinone vs leuprolin
Painful intercourse ‐ Dyspareunia · women with symptomatic endometriosis
1 finding from 1 review
- no estimate extracted1 study · 52 participantsLow
Gestrinone vs leuprolin
Amenorrhoea · women with symptomatic endometriosis
Gestrinone may leads to lower amenorrhoea compared with leuprolin (low certainty).
1 finding from 1 review
- OR 0.04 [0.01, 0.38]1 study · 49 participantsLow
Gestrinone vs leuprolin
Percentage days bleeding or spotting (questionnaire) · women with symptomatic endometriosis
Gestrinone may leads to higher spotting or bleeding compared with leuprolin (low certainty).
1 finding from 1 review
- OR 22.92 [2.64, 198.66]1 study · 49 participantsLow
Gestrinone vs leuprolin
Side effects ‐ hot flushes · women with symptomatic endometriosis
Gestrinone may leads to lower side effects: hot flushes compared with leuprolin (low certainty).
1 finding from 1 review
- OR 0.2 [0.06, 0.63]1 study · 55 participantsLow
Mifepristone (all doses) vs placebo
Prevalence of dyspareunia · women with symptomatic endometriosis
Mifepristone may leads to lower prevalence of dyspareunia compared with placebo (low certainty).
1 finding from 1 review
- OR 0.23 [0.1, 0.51]1 study · 223 participantsLow
Mifepristone (all doses) vs placebo
Side effects ‐ amenorrhoea · women with symptomatic endometriosis
Mifepristone leads to higher side effects: amenorrhoea compared with placebo (high certainty).
1 finding from 1 review
- OR 686.16 [92.29, 5101.33]1 study · 360 participantsHigh
Mifepristone (all doses) vs placebo
Side effects ‐ hot flushes · women with symptomatic endometriosis
Mifepristone leads to higher side effects: hot flushes compared with placebo (high certainty).
1 finding from 1 review
- OR 28.79 [3.93, 210.73]1 study · 360 participantsHigh
Gestrinone vs danazol
Pelvic pain · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes pelvic pain: none or mild compared with danazol (very low certainty).
1 finding from 1 review
- OR 0.71 [0.33, 1.56]2 studies · 230 participantsVery low
Gestrinone vs danazol
Dysmenorrhoea: none or mild · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes dysmenorrhoea: none or mild compared with danazol (very low certainty).
1 finding from 1 review
- OR 0.72 [0.39, 1.33]2 studies · 214 participantsVery low
Gestrinone vs danazol
Dyspareunia: none or mild · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes dyspareunia: none or mild compared with danazol (very low certainty).
1 finding from 1 review
- OR 0.83 [0.37, 1.86]2 studies · 222 participantsVery low
Gestrinone vs danazol
Side effects ‐ hirsutism · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes side effects: hirsutism compared with danazol (very low certainty).
1 finding from 1 review
- OR 2.63 [1.6, 4.32]2 studies · 302 participantsVery low
Gestrinone vs danazol
Decreased breast size · women with symptomatic endometriosis
Gestrinone may leads to lower decreased breast size compared with danazol (low certainty).
1 finding from 1 review
- OR 0.62 [0.38, 0.98]2 studies · 302 participantsLow
SPRM vs placebo
Quality of life: change in symptom severity score · women with uterine fibroids
1 finding from 1 review
- Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 171 participantsModerate
SPRM vs leuprolide acetate
Abnormal uterine bleeding: amenorrhoea · uterine fibroids
SPRM showed no clear difference in abnormal uterine bleeding: amenorrhoea compared with leuprolide acetate (moderate certainty).
1 finding from 1 review
- Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes onlyOR 1.14 [0.6, 2.16]1 study · 280 participantsModerate
SPRM vs leuprolide acetate
Pelvic pain · uterine fibroids
1 finding from 1 review
- Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 281 participantsModerate
SPRM vs leuprolide acetate
Adverse effects: SPRM‐associated endometrial changes · uterine fibroids
SPRM probably leads to higher adverse effects: SPRM‐associated endometrial changes compared with leuprolide acetate (moderate certainty).
1 finding from 1 review
- Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes onlyOR 10.45 [5.38, 20.33]1 study · 301 participantsModerate
SPRM vs placebo
Quality of life: change in health‐related quality of life score · women with uterine fibroids
1 finding from 1 review
- Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 200 participantsModerate
SPRM vs placebo
Abnormal uterine bleeding: change in menstrual blood loss · women with uterine fibroids
1 finding from 1 review
- Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 310 participantsModerate
SPRM vs placebo
Abnormal uterine bleeding: amenorrhoea · women with uterine fibroids
SPRM probably leads to higher abnormal uterine bleeding: amenorrhoea compared with placebo (moderate certainty).
1 finding from 1 review
- Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes onlyOR 82.5 [37.1, 183.9]7 studies · 590 participantsModerate